

1 Changes in vaginal *Ureaplasma* and *Lactobacillus* due to antibiotic regimen for
2 premature rupture of membranes

3

4 Short title: Changes in vaginal *Ureaplasma* and *Lactobacillus* due to antibiotic regimen

5

6

7 Authors

8 Haruna Kawaguchi ^{1,2} ¶*, Yukiko Nakura ^{2&}, Ryo Yamamoto ¹, Shusaku Hayashi ¹,

9 Makoto Takeuchi ³, Keisuke Ishii ¹, Itaru Yanagihara ² ¶

10 1) Department of Maternal Fetal Medicine, Osaka Women's and Children's Hospital,
11 Osaka, Japan

12 2) Department of Developmental Medicine, Research Institute, Osaka Women's and
13 Children's Hospital, Osaka, Japan

14 3) Department of Pathology, Osaka Women's and Children's Hospital, Osaka, Japan

15

16 *Correspondence author

17 E-mail: haruna@wch.opho.jp

18 ¶ These authors contributed equally to this work.

19 &These authors also contributed equally to this work.

20

21

22 Abstract

23 Preterm premature rupture of membranes (PPROM) is associated with preterm delivery
24 and neonatal complications. PPRM is often complicated by intra-amniotic inflammation
25 and/or microbial invasion of the amniotic cavity with *Ureaplasma* or *Mycoplasma*.
26 Various prophylactic antibiotic therapies have been proposed to prolong latency between
27 PPRM and delivery, reduce the risk of clinical chorioamnionitis, and improve neonatal
28 complications. However, information on the potential of azithromycin administration to
29 reduce the microbial load of vaginal *Ureaplasma* and *Mycoplasma* remains lacking. This
30 prospective cohort study included singleton pregnancies managed with prophylactic
31 antibiotics for PPRM at less than 36 weeks of gestation. All patients received the
32 standard antibiotic regimen for PPRM, which consisted of a single oral azithromycin
33 and intravenous ampicillin every for 2 days followed by 5 days of oral amoxicillin.
34 Vaginal swabs samples were collected when PPRM was confirmed and after the
35 antibiotic regimen administration. The main outcome measures were to investigate the
36 changes in vaginal *Ureaplasma*, *Mycoplasma*, and *Lactobacillus spp.* due to the antibiotic
37 regimen. In addition, the association between the presence and changes in vaginal
38 *Ureaplasma* and *Mycoplasma*, pregnancy outcomes, and neonatal complications were
39 examined. Out of 82 eligible PPRM, 51 had positive vaginal *Ureaplasma*. Thirty-six

40 patients (52.2%) completed the antibiotic regimen. Among those with positive vaginal
41 *Ureaplasma* who completed the antibiotic regimen, 75% experienced an increase in
42 vaginal *Ureaplasma* levels. For those who delivered before completing all antibiotic
43 doses, 40% had increased vaginal *Ureaplasma* levels. Furthermore, the antibiotic regimen
44 resulted in decreased *Lactobacillus spp.* in almost all cases. However, vaginal
45 *Ureaplasma* changes were not found to be associated with neonatal sepsis or
46 bronchopulmonary dysplasia. This suggests that *Ureaplasma* became resistant to
47 azithromycin. Future studies are needed to revalidate current antibiotic therapy for
48 PPROM.

49

50 Keywords: Azithromycin, bronchopulmonary dysplasia, funisitis, histological

51 chorioamnionitis, neonatal infection

52

53 Introduction

54 Preterm premature rupture of membranes (PPROM) occurs in 2%–3% of
55 pregnancies and is associated with preterm delivery, neonatal complications, and
56 maternal sepsis.(1-4) PPRM is often complicated by intra-amniotic inflammation
57 and/or microbial invasion of the amniotic cavity with *Ureaplasma* or *Mycoplasma*. (5)
58 Both are linked to neonatal infections and chronic lung disease. (6) Various
59 prophylactic antibiotic regimens were proposed to prolong the latency between PPRM
60 and delivery, reduce the risk of clinical chorioamnionitis, and improve neonatal
61 outcomes. (7-10) The American College of Obstetricians and Gynecologists
62 recommends using erythromycin and ampicillin, but a regimen with azithromycin has
63 been suggested as an alternative to erythromycin. (8, 11, 12)
64 At our institution, patients with PPRM receive a standard antibiotic regimen
65 consisting of a single oral dose of azithromycin and intravenous ampicillin for 2 days
66 followed by 5 days of oral amoxicillin. However, it is unclear whether administering
67 azithromycin can reduce the microbial load of vaginal *Ureaplasma* and *Mycoplasma*
68 DNA. Therefore, this study aimed to investigate the changes in vaginal *Ureaplasma*,
69 *Mycoplasma*, and *Lactobacillus*, as well as maternal blood *Ureaplasma*, resulting from
70 the antibiotic regimen used for PPRM cases. In addition, the association between the

71 presence and changes in vaginal *Ureaplasma* and *Mycoplasma*, pregnancy outcomes,

72 and neonatal complications were examined, and that aim was achieved.

73 Materials and Methods

74 This single-center, prospective cohort study included singleton pregnancies
75 managed with prophylactic antibiotics for PPRM at less than 36 weeks of gestation
76 between October 2019 and December 2021. Patients under the age of 20, those who
77 received other antibiotics within 2 weeks of PPRM, and those allergic to ampicillin
78 and azithromycin were excluded. All relevant national regulations and institutional
79 policies were compiled, and the study was conducted under the tenets of the Helsinki
80 Declaration. It was approved by the ethical review board of Osaka Women's and
81 Children's Hospital (approval number, 1211; date of approval, June 3, 2019). Written
82 informed consent was obtained from all study subjects. Recruitment of subjects for this
83 study began on October 1, 2019 and ended on December 31, 2021. The standard
84 deviation of the amount of vaginal *Ureaplasma* colonization was $10^{2.7}$. To have a 90%
85 power to detect changes above 10^2 colony-forming units/mL, the study aimed to enroll
86 80 patients.

87 The perinatal management protocol for PPRM at our institution is as follows.
88 The diagnosis of PPRM is confirmed by observing amniotic fluid leakage from the
89 cervix or pooling in the vagina, along with positive diagnostic tests measuring vaginal
90 pH. In cases where the diagnosis is not clearly confirmed, an immunochromatographic

91 strip test with insulin-like growth factor-binding protein-1 (ActimProma[®]) is used to
92 detect amniotic fluid in the vagina or ultrasound evaluation is used to confirm the
93 presence of oligohydramnios. All patients were admitted to the hospital and received the
94 standard antibiotic regimen for PPRM before 36 weeks of gestation with intravenous
95 ampicillin (2 g dose every 6 hours) for 48 hours and single oral azithromycin (1 g dose)
96 followed by oral amoxicillin (500 mg dose every 8 hours) for 5 days. Betamethasone
97 was administered for patients with gestational age less than 34 weeks and imminent
98 delivery. Intravenous magnesium sulfate and/or ritodrine hydrochloride and/or oral
99 nifedipine as tocolytic agents were administered when patients have short cervical
100 length and frequent uterine contraction. Indications for delivery included clinical
101 chorioamnionitis, onset of labor, nonreassuring fetal status, or gestational age beyond
102 36 weeks. Clinical chorioamnionitis was diagnosed based on the presence of maternal
103 fever ($\geq 38.0^{\circ}\text{C}$) and two or more clinical signs: maternal leukocytosis (white blood cell
104 count $>15,000/\text{mm}^3$), maternal tachycardia (heart rate > 100 beats/min), fetal
105 tachycardia (heart rate > 160 beats/min), uterine tenderness, and purulent or foul-
106 smelling amniotic fluid or vaginal discharge. (13)

107 Vaginal swabs and maternal blood samples were collected from women when
108 the diagnosis of PPRM was confirmed. The quantity of vaginal secretions was

109 measured by weighing the swab tube before and after the collection. Vaginal swabs
110 were taken from the lateral vaginal walls and the anterior and posterior fornix, and they
111 were transferred to a cobas® polymerase chain reaction (PCR) Media Dual Swab
112 Sample Kit from Roche Diagnostics GmbH, Germany. Vaginal swabs and maternal
113 blood samples were retaken after the completion of the antibiotic regimen. Scrapings of
114 the placental surface were also performed. If delivery occurred before the completion of
115 the regimen, vaginal swabs and maternal blood samples were collected before the
116 delivery. These results were not available to managing clinicians. The amount and
117 species of *Ureaplasma* collected from the vaginal secretions, along with the amount of
118 *Lactobacillus* spp. and *Mycoplasma (M.) hominis* and the presence of inerolysin (pore-
119 forming toxin produced by *Lactobacillus (L.) iners* that can cause preterm labor) were
120 determined using real-time PCR. The amount of *Ureaplasma* was also measured from
121 maternal blood and placental surface. An increase or decrease of 10^2 or more in DNA
122 copy numbers was considered significant.

123 This study investigated neonatal and infant mortality and any of the following
124 adverse perinatal outcomes for up to 6 months of age: neonatal intensive care unit
125 admission, mechanical ventilation, respiratory distress syndrome, retinopathy of
126 prematurity, intraventricular hemorrhage 3 or 4 grade, periventricular leukomalacia,

127 necrotizing enterocolitis, neonatal sepsis, bronchopulmonary dysplasia (BPD), and
128 congenital anomaly. BPD is a chronic lung disease, which is most commonly seen in
129 premature infants requiring respiratory support, including oxygen supplementation at 36
130 weeks corrected gestational age. (14) Neonatal sepsis is defined as the presence of a
131 positive blood culture. (15)

132 In this study, changes in vaginal *Ureaplasma*, *Mycoplasma*, and *Lactobacillus*
133 are divided into two groups: complete and incomplete antibiotic protocols. Cases of
134 complete protocol are defined as cases in which all antibiotic regimens had been
135 completed. Cases of incomplete protocol are those who delivered in the middle of their
136 antibiotic regimen, but all of them had received at least one intravenous ampicillin and
137 oral azithromycin administration.

138

139 DNA extraction and quantitative real-time PCR of *Ureaplasma*

140 DNA was extracted from vaginal swab and maternal blood samples using a Maxwell®

141 RSC Blood DNA Kit (AS1400, Promega, Japan). The DNA copy number of

142 *Ureaplasma* was measured using QuantStudio 5Real-Time PCR System (Thermo Fisher

143 Scientific) targeted for the 16S ribosomal RNA gene. The amplification reaction

144 mixtures comprised 5 mL of TaqMan Fast Advanced Master Mix (Thermo Fisher

145 Scientific), primers (0.9 μ M each), probe (Thermo Fisher Scientific, 0.25 μ M), and 1 μ L
146 of DNA sample; this was adjusted to 10 μ L with DDW. The primers and probe used
147 were as follows: 16S-Urea F1(AGGCATGCGTCTAGGGTAGGA), 16S-Urea
148 R1(ACGTTCTCGTAGGGATACCTTGTTA), and 16S-Urea-FAM-MGB
149 probe (FAM-CGGTGACTGGAGTTAA-MGB).

150 The PCR conditions were as follows: predenaturation at 95°C for 20 s, 40 cycles of
151 denaturation at 95°C for 1 s, and annealing at 58 C for 20 s.

152 The standard curve of *Ureaplasma* was determined using serial dilutions with copy
153 numbers of 1.0×10^1 to 1.0×10^6 copies per reaction mixture by real-time PCR. In each
154 run with clinical specimens, negative control and standards were included. To
155 differentiate *Ureaplasma (U.) parvum* from *U. urealyticum*, the following primers and
156 probes were used: ureG F2(CAACATTTAGTCCAGATTTAG), ureG
157 R2(TAGCACCAACATAAGGAG), Up-FAM-MGB probe (FAM-
158 TTGACCACCCTTACGAG-MGB), and Uu-VIC-MGB probe (VIC-
159 TTGTCCGCCTTTACGAG-MGB). The amplification reaction mixtures comprised 5
160 mL of TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific), primers (0.9 μ M
161 each), probes (Thermo Fisher Scientific, 0.2 μ M each), and 1 μ L of sample DNA; this
162 was adjusted to 10 μ L with DDW.

163

164 Quantitative real-time PCR analysis of *M. hominis*

165 The primers and probe used were as follows:

166 Mh-yidC-F(ACCCGGTTTAGTGAGTTTGCT), Mh-yidC-R

167 (CCTCAGTTTATTGCATTGCCA), and Mh-yidC-VIC probe (VIC-

168 AACAAAGCAACCTGATATT-MGB). The PCR conditions were as follows:

169 predenaturation at 95°C for 20 s, 35 cycles of denaturation at 95°C for 1 s, and

170 annealing at 60°C for 20 s.

171

172 Quantitative real-time PCR of *Lactobacillus* species and inerolysin detection

173 The primers for *Lactobacillus* spp. used were Lacto-F

174 (TGGAACAGRTGCTAATACCG) and Lacto-R

175 (GTCCATTGTGGAAGATTCCC).(16) The primers for inerolysin were; inerolysin-

176 F(CGTGGTCGTACATCAGGCTT) and inerolysin-

177 R(TTCTCCACCATTCCCATGCC).

178 PCRs were performed in a reaction volume of 10 µL, each containing 0.5 µM of

179 inerolysin-F and inerolysin-R primers, 5 µL of PowerUP™ SYBR™ Green Master Mix

180 (Thermo Fisher Scientific), and 1.0 µL of genomic DNA. PCR amplification was

181 performed under the following conditions: initial cycle of 95°C for 2 min, 35 cycles of

182 95°C for 1 s, 58°C for 15 s, and 72°C for 60 s.

183

184 2.4 Statistical analysis

185 Categorical and continuous variables were analyzed using chi-square or Fisher's exact

186 tests and compared using Kruskal–Wallis test. Multivariate logistic regression analyses

187 were performed to examine the adjusted odds ratios (aOR) and 95% confidence

188 intervals (CI) for changes in *Ureaplasma* and perinatal outcomes. Statistical

189 significance was set at $P < 0.05$. Two-sided P-values were reported, and analyses were

190 conducted using a JMP software (version 14; SAS Institute, Cary, NC, USA).

192 Results

193 In total, 82 patients with PPRM were included, and 51 were positive for
194 vaginal *Ureaplasma*. Thirty-six patients (52.2%) completed the standard antibiotic
195 regimen. (Figure 1) Of those who had positive vaginal *Ureaplasma* and completed the
196 standard antibiotic regimen, vaginal *Ureaplasma* increased in 18 patients (75%).

197 Among patients with positive vaginal *Ureaplasma* who delivered before the completion
198 of all antibiotic doses, vaginal *Ureaplasma* increased in eight patients (40%).

199

200 Fig 1. Flowchart of the study population.

201 A total of 82 patients with PPRM were eligible for this study. Vaginal *Ureaplasma*
202 was positive in 51 patients and negative in 31 patients. Of the patients who had positive
203 vaginal *Ureaplasma* and completed the standard antibiotic regimen, 18 (75%) had
204 increased vaginal *Ureaplasma* after treatment. Among patients with a positive vaginal
205 *Ureaplasma* delivered before completion of all antibiotic doses, vaginal *Ureaplasma*
206 increased in eight patients (40%).

207 PPRM, preterm premature rupture of membranes; NEG, negative

208 * intravenous 2 g ampicillin every 6 hours for 2 days, a single oral dose of 1 g

209 azithromycin, and 5 days of oral 500 mg amoxicillin every 8 hours.

210 Fig 2. The change of microbial load of vaginal *Ureaplasma* DNA before and after
211 antibiotic regimen.

212 There were many cases of increased vaginal *Ureaplasma*, especially in patients who had
213 completed the antibiotic regimen.

214 * intravenous ampicillin 2 g every 6 hours for 2 days and a single oral dose of
215 azithromycin 1 g followed by 5 days of oral amoxicillin 500 mg every 8 hours.

216 Fig 3. The change of microbial load of vaginal *Lactobacillus* spp. DNA before and
217 after antibiotic regimen.

218 Almost all *Lactobacillus* spp. were decreased or disappeared after the antibiotic
219 regimen, especially in the cases that completed the antibiotic regimen.

220 * intravenous 2 g ampicillin every 6 hours for 2 days, a single oral dose of 1 g
221 azithromycin, and 5 days of oral 500 mg amoxicillin every 8 hours.

222 Table 1 shows the maternal characteristics and perinatal findings classified into
223 three groups based on vaginal *Ureaplasma* changes: *Ureaplasma*-negative before and
224 after the antibiotic regimen, *Ureaplasma*-positive that decreased after the antibiotic
225 regimen, and *Ureaplasma*-positive that increased after the antibiotic regimen.

226

227 Table 1. Maternal characteristics and perinatal findings, classified into three groups

228 based on vaginal *Ureaplasma* changes by antibiotic treatment

	Total	<i>Ureaplasma</i> (-) at the time of PPROM	<i>Ureaplasma</i> (+) at the time of PPROM		<i>p</i>
			Decreased after treatment	Increased after treatment	
	N = 69	N = 24	N = 18	N = 27	
maternal age at delivery	33(23–46)	35 (26–46)	31.5 (22–41)	33 (23–42)	0.21
nulliparous	40	10 (41.7)	14 (77.8)	16 (59.3)	0.06
history of preterm birth	4	1 (4.2)	0	3 (11.1)	0.27
Obesity (BMI ≥25)	11	4 (16.7)	4 (22.2)	3 (11.1)	0.6
ART	10	3 (12.5)	2 (11.1)	5 (18.5)	0.74
tobacco use during pregnancy	4	1 (4.2)	1 (5.6)	2 (7.4)	0.88
CHT	1	1 (4.2)	0	0	-
DM	0	0	0	0	-

history of cervical conization	7	1 (4.2)	0	6 (22.2)	0.026
cerclage	6	2 (8.3)	2 (11.1)	2 (7.4)	0.91
antenatal corticosteroid	38	14 (58.3)	10 (55.6)	14 (51.9)	0.9
tocolysis ^a	39	13 (54.2)	10 (55.6)	16 (59.3)	0.93
HDP	4	2 (8.3)	0	2 (7.4)	0.47
GDM	7	1 (4.6)	3 (17.6)	3 (11.5)	0.42
antibiotics	69	24 (100)	18 (100)	27 (100)	-
complete protocol ^b	36	11 (45.8)	6 (33.3)	19 (70.4)	0.038
azithromycin	69	24 (100)	18 (100)	27 (100)	-
GA at PPROM	31 + 6 (12 + 5~35 + 6)	32 + 3 (20 + 0 ~35 + 6)	32 + 2 (17 + 6~35 + 3)	31 + 3 (12 + 5~35 + 2)	0.43
GA at delivery	33 + 1 (17 + 5~36 + 4)	33 + 2 (23 + 0 ~36 + 4)	33 + 3 (18 + 1~36 + 1)	32 + 4 (17 + 5~36 + 3)	0.83
Latency ^c	7 (0-86)	5 (0-86)	3.5 (0-21)	10 (2-52)	0.012

Latency < 7days	33	13 (54.2)	12 (66.7)	8 (29.6)	0.03
CS	25	10 (41.7)	3 (16.7)	12 (44.4)	0.13
hCAM	39	12 (54.6)	8 (50)	19 (76)	0.17
Funisitis	30	9 (40.9)	4 (25)	17 (68)	0.02

229 Data are expressed as the median (range) or n (%)

230 ^a Tocolysis agents are intravenous magnesium sulfate and/or ritodrine hydrochloride
231 and/or oral nifedipine.

232 ^b Complete protocol is defined as the cases in which all standard antibiotic regimens
233 (intravenous 2 g ampicillin every 6 hours for 2 days, one oral dose of 1 g azithromycin,
234 and 5 days of oral 500 mg amoxicillin every 8 hours) had been completed.

235 ^c The latency is defined as the period between PPRM and delivery.

236 BMI, body mass index; ART, assisted reproductive technology; CHT, chronic
237 hypertension; DM, diabetes mellitus; HDP, hypertensive disorders of pregnancy; GDM,
238 gestational diabetes mellitus; GA, gestational age; PPRM, preterm premature rupture
239 of membranes; CS, cesarean section; hCAM, histological chorioamnionitis

240

241 The median gestational week at PPRM and delivery did not differ among the
242 three groups. However, latency from PPRM to delivery was significantly prolonged in

243 the group with increased *Ureaplasma* after the antibiotic regimen. There was no
244 difference in the incidence of histological chorioamnionitis (hCAM), but funisitis was
245 significantly more common in the group with increased *Ureaplasma* after the antibiotic
246 regimen ($p = 0.02$).

247 Figure 2 shows the changes in vaginal *Ureaplasma* spp. before and after the
248 antibiotic regimen. The median microbial load of vaginal *Ureaplasma* DNA at the time
249 of PPROM was 1.9×10^7 ($1.8 \times 10^2 - 4.6 \times 10^9$). Many cases had increased vaginal
250 *Ureaplasma*, especially in patients who completed the antibiotic regimen. As shown in
251 Figure 3, *Lactobacillus* spp. decreased after the antibiotic regimen in almost all cases.
252 Table 2 shows the vaginal and maternal blood *Ureaplasma*, vaginal *M. hominis*,
253 *Lactobacillus* spp., and ineroysin classified by vaginal *Ureaplasma* changes. All *M.*
254 *hominis*-positive cases were positive for vaginal *Ureaplasma*. Three patients had a
255 positive vaginal *M. hominis* result at the time of PPROM and did not decrease in all
256 cases after antibiotic regimen, but rather turned positive in three new cases. The loss of
257 *Lactobacillus* spp. was more common in patients who completed the antibiotic regimen,
258 especially in the group with increased *Ureaplasma*. hCAM and funisitis were more
259 common in those with completed antibiotic regimen, regardless of vaginal *Ureaplasma*
260 changes due to the antibiotic regimen and presence of *Ureaplasma* at the time of

261 PPRM (aOR,7.5; 95% CI; 2.1–26.6; $P = 0.002$, aOR4.5; 95%CI 1.4–11.4; $P = 0.01$,
 262 respectively). Among incomplete the antibiotic regimen, there were less funisitis in the
 263 group with decreased *Ureaplasma* due to antibiotic therapy than in the group with
 264 increased or negative *Ureaplasma* at the time of PPRM.

265

266 Table 2. *Ureaplasma* in vagina and maternal blood, vaginal *Mycoplasma hominis*,
 267 vaginal *Lactobacillus spp*, and inerolysin classified by whether the antibiotic regimen
 268 was completed or not and how vaginal *Ureaplasma* was changed

			complete protocol			uncomplete protocol		
			<i>Ureaplasma</i> (+) at the time of PPRM		<i>Ureapl</i> <i>asma</i> (-) at the time of PPRO M	<i>Ureaplasma</i> (+) at the time of PPRM		<i>Urea</i> <i>plasm</i> <i>a</i> (-) at the time of PPRO M
			increased <i>Ureaplas</i> <i>ma</i> after antibiotic regimen	decreased <i>Ureaplas</i> <i>ma</i> after antibiotic regimen		increase d <i>Ureapla</i> <i>sma</i> after antibioti c regimen	decreased <i>Ureaplas</i> <i>m</i> <i>a</i> after antibiotic regimen	
		N	18	6	12	8	12	13
befor	vaginal	Up	15	3	—	5	10	—

e antib iotic regi men	<i>Ureaplasma</i>	Uu	3	2	—	3	3 (duplication1)	—
	<i>a</i>	unkno wn	0	1	—	0	0	—
	vaginal <i>Ureaplasma</i> DNA (cp/mL)		1.8×10^7 (1.7×10^4 – 2.3×10^8)	6.8×10^8 (1.8×10^2 – 4.6×10^9)	—	1.1×10^7 (3.7×10^5 – 2.2×10^8)	1.2×10^8 (6.8×10^2 – 1.4×10^9)	—
	maternal blood <i>Ureaplasma</i> (+)		0	1	0	0	0	0
	vaginal <i>M. hominis</i> (+)		2 (11.1)	0	0	0	1 (8.3)	0
	vaginal <i>Lactobacillus</i> (+)		15 (83.3)	6 (100)	11 (91.7)	8 (100)	12 (100)	13 (100)
	Inerolysin (+) among <i>Lactobacillus</i>		9/15 (60)	3/6 (50)	6/11 (54.5)	4/8 (50)	10/12 (83.3)	3/13 (23.1)
after antib iotic regi men	vaginal <i>Ureaplasma</i>		4.8×10^7 (2.8×10^7 – 6.9×10^9)	8.0×10^6 (0 – 7.9×10^7)	1.7×10^6 (positive conversion1)	4.1×10^8 (8.7×10^6 – 3.4×10^{10})	4.2×10^6 (0 – 7.3×10^8)	—
	maternal blood <i>Ureaplasma</i> (+)		0	1 (16.7)	0	1 (12.5)	0	0
	vaginal <i>M. hominis</i> (+)		4 (22.2)	1 (16.7)	0	0	1 (8.3)	0

vaginal <i>Lactobacillus</i>	decrease	15 (100)	6 (100)	10 (90.9)	8 (100)	12 (100)	11 (84.6)
	loss	12 (80)	4 (66.7)	5 (45.4)	4 (50)	4 (33.3)	2 (15.4)
	Inerolysin (+) among <i>Lactobacillus</i>	1/6 (16.7)	0	4/6 (66.7)	0	1/8 (12.5)	0
<i>Ureaplasma</i> in the placenta (unexamined)		14 (87.5) (n = 2)	3 (75) (n = 2)	0 (n = 1)	8 (100)	8 (72.7) (n = 1)	1 (n = 1)
hCAM (unexamined)		14 (82.3) (n = 1)	4 (100) (n = 2)	9 (81.8) (n = 1)	4 (57.1) (n = 1)	4 (33.3)	4 (33.3) (n = 1)
Funisitis		12 (70.6)	3 (60)	7 (63.6)	4 (57.1)	1 (8.3)	2 (16.7)

269

270 Data are expressed as the median (range) or n (%).

271 PPRM, preterm premature rupture of membranes; Up, *Ureaplasma parvum*; Uu,

272 *Ureaplasma urealyticum*; M. *hominis*, *Mycoplasma hominis*; hCAM, histological

273 chorioamnionitis

274

275 Table 3 shows the neonatal complications according to vaginal *Ureaplasma*

276 changes. Vaginal *Ureaplasma* changes were not associated with neonatal intensive care

277 unit admission, neonatal sepsis, mechanical ventilation, or BPD. However, BPD was
278 more frequent in those who completed protocol than in those who did not complete the
279 protocol, regardless of vaginal *Ureaplasma* changes due to the antibiotic regimen,
280 presence of *Ureaplasma* at the time of PPRM, and gestational age at delivery. (aOR,
281 7.2; 95%CI 1.3–40.1; $P = 0.02$)
282 Table 3. The neonatal complications according to vaginal *Ureaplasma* changes
283 due to the antibiotic regimen

	Total	<i>Ureaplasma</i> - negative	<i>Ureaplasma-positive</i>		
			decreased after treatment	increased after treatment	
	N = 69	N = 24	N = 18	N = 27	
Stillbirth	4	1 (4.2)	1 (5.6)	2 (7.4)	
neonatal death	1	0	0	1 (3.7)	
infant death	2	1	0	1 (3.7)	
delivery at other hospital	4	1	2	1	
infant outcome ^a	N = 60	N = 22	N = 15	N = 23	<i>p</i>
birth weight(g)	2018 (520– 3010)	1957 (692– 2918)	2172 (864– 2958)	2016 (520– 3010)	0.97
NICU admission	54 (90)	21 (95.5)	14 (93.3)	19 (82.6)	0.32
male infant	37 (61.7)	15 (68.2)	10 (66.7)	12 (52.3)	0.49
Apgar score (5) < 7	7 (11.7)	3 (13.6)	2 (13.3)	2 (8.7)	0.85
pH < 7.1	0	0	0	0	-
mechanical ventilation	27 (45)	9 (40.9)	5 (33.3)	13 (56.5)	0.33
RDS	18 (30)	6 (27.3)	4 (26.7)	8 (34.8)	0.82
ROP	13 (21.7)	5 (22.7)	3 (20)	5 (21.7)	0.98

IVH 3,4	0	0	0	0	-
PVL	0	0	0	0	-
NEC	1 (1.7)	1 (4.5)	0	0	0.42
neonatal sepsis	5 (8.3)	2 (9.1)	1 (6.7)	2 (8.7)	0.96
BPD	15 (25)	5 (22.7)	4 (26.7)	6 (26.1)	0.95
congenital anomaly	11 (18.3)	5 (22.7)	3 (20)	3 (13.0)	0.69

284

285 Data are expressed as the median (range) or n (%).

286 ^aAfter excluding four cases delivered at other hospitals, four stillbirths, and one early

287 neonatal death, 60 cases were included in the study of infant complications.

288 NICU, neonatal intensive care unit; RDS, respiratory distress syndrome; ROP,

289 retinopathy of prematurity; IVH, intraventricular hemorrhage; PVL, periventricular

290 leukomalacia; NEC, necrotizing enterocolitis; BPD, bronchopulmonary dysplasia

291

292

293 Discussion

294 Almost all *Lactobacillus* spp. decreased or disappeared, while most vaginal
295 *Ureaplasma* and *M. hominis* increased after the antibiotic regimen, particularly in
296 patients who completed the regimen. Patients with increased vaginal *Ureaplasma* had
297 longer latency. This result did not indicate that cases of increased *Ureaplasma* would
298 have a longer latency period. Rather, the longer period reflected *Ureaplasma* that was
299 not reduced by antibiotic therapy grew intravaginally. The longer latency from PPRM
300 may increase the likelihood of ascending infection of *Ureaplasma* to the amnion despite
301 the antibiotic therapy. The possibility of avoiding invasive amniocentesis was
302 considered if *Ureaplasma* could be detected in maternal blood in the presence of
303 intrauterine *Ureaplasma* infection. However, it was impractical because *Ureaplasma* in
304 maternal blood was undetectable in most cases.

305 Antibiotics were recommended for women with PPRM to prolong the
306 delivery latency interval and reduce chorioamnionitis and neonatal sepsis.(8, 9, 17, 18)
307 A regimen of intravenous ampicillin and erythromycin followed by oral amoxicillin and
308 erythromycin has been commonly used. (8) Recently, azithromycin has been used
309 instead of erythromycin because of its low cost, better side effect profile, ease of
310 administration, and antibiotic resistance. The resistance of *Ureaplasma* and

311 *Mycoplasma* to erythromycin was reported to be over 80%. (19) Azithromycin was
312 associated with a similar latency interval and lower rate of clinical chorioamnionitis for
313 women with PPROM.(12, 20) Tanaka reported the eradication of *Ureaplasma* in the
314 amniotic fluid of patients with PPROM treated with intravenous ampicillin–sulbactam
315 and oral azithromycin.(21) Kacerovsky showed that intravenous clarithromycin was
316 related to the reduced *Ureaplasma* DNA load in the amniotic fluid of patients with
317 PPROM.(10) Conversely, Gomez reported that antibiotic administration (ceftriaxone,
318 clindamycin, and erythromycin for 10–14 days) rarely eradicates intra-amniotic
319 infection in patients with preterm PROM.(22) A report showed that azithromycin
320 effectively eradicated respiratory tract *Ureaplasma* colonization in preterm infants. (23)
321 In this study, most vaginal *Ureaplasma* was increased after the antibiotic regimen,
322 suggesting an increasing resistance of *Ureaplasma* to azithromycin. In previous reports,
323 the resistance rates of *U. urealyticum* and *M. hominis* to azithromycin also increased by
324 about 14%–19.5%. (24, 25)

325 In this study, there was an increased frequency of hCAM, funisitis, and BPD in
326 cases that completed the antibiotic regimen. An increased vaginal *Ureaplasma*
327 increased the frequency of funisitis but not the incidence of neonatal infection and BPD.
328 These suggest that even if the antibiotic regimen contributes to a prolonged gestational

329 age, it may increase the frequency of intrauterine infection or neonatal infection from
330 proliferated *Ureaplasma* and decreased *Lactobacillus* spp. Many studies presented that
331 *Ureaplasma* was associated with adverse pregnancy outcomes and neonatal morbidities,
332 such as preterm delivery, PPRM, chorioamnionitis, BPD,(6, 26) intraventricular
333 hemorrhage,(27) and necrotizing enterocolitis.(28) Macrolides have anti-inflammatory
334 properties that might reduce lung damage in preterm infants and treat bacterial
335 infections(29); they reduce BPD in preterm infants. (30, 31) In this study, respiratory
336 samples from infants were not obtained for *Ureaplasma* culture, so it was unknown
337 whether the infants had *Ureaplasma* infection. The sample size was insufficient to
338 validate the neonatal morbidity, so further research is needed.

339 *Lactobacillus*, the most frequently isolated microorganism from a healthy
340 human vagina, is touted to prevent the invasion of pathogens and ensure vaginal
341 epithelial homeostasis. (32) The loss of *Lactobacillus* and increase in Gram-negative
342 rods, such as *Gardnerella vaginalis*, lead to bacterial vaginosis. (33) In a recent study,
343 *L. crispatus*, *L. gasseri*, *L. jensenii*, and *L. iners*, were the most frequently isolated in the
344 vaginas of healthy childbearing age or pregnant women. (34) A vaginal microbiota that
345 is rich in *L. crispatus*, *L. gasseri*, and *L. jensenii* is often associated with a lower risk of
346 bacterial vaginosis and preterm birth. Conversely, *L. iners* may play a role in the

347 pathogenesis of bacterial vaginosis associated with preterm birth.(35, 36) *L. iners* alone
348 detected in vaginal smears of healthy women in early pregnancy might be related to
349 preterm delivery.(35) *L. iners* secretes the cholesterol-dependent cytolysins (CDC),
350 inerolysin, as well as one of the CDC family, vaginolysin, produced by *G. vaginalis*.
351 (37) In this study, about half of the cases had inerolysin, which may be related to the
352 fact that the subjects in this study were cases of PPRM. There was no difference in the
353 increase in vaginal *Ureaplasma* with or without inerolysin. *Lactobacillus* spp. was
354 decreased after the antibiotics therapy regardless of the presence or absence of
355 inerolysin. It is unclear whether *Lactobacillus* spp., reduced by antibiotic therapy, will
356 recover spontaneously. It may be challenging to reduce *Ureaplasma* with this antibiotic
357 therapy; we may rather focus on *Lactobacillus* formulations.

358 The strength of this study is that it is the first to investigate both vaginal
359 *Ureaplasma* and *Lactobacillus* changes caused by ampicillin and azithromycin
360 regimens. This was also an examination at a single institution with a uniform
361 management policy. However, it has several limitations. In this study, vaginal cultures
362 were collected rather than from amniotic fluid through transabdominal amniocentesis,
363 which does not directly indicate amniotic fluid infection. There were three reasons why
364 the specimens were vaginal secretions. First, the purpose of this study was to observe

365 changes in both *Ureaplasma* and *Lactobacillus* due to antibiotic administration. Second,
366 in PPRM cases, amniotic fluid testing after antibiotic administration might not be
367 available due to the almost complete loss of amniotic fluid in the uterine cavity or the
368 rapid onset of labor. Third, amniocentesis was invasive. In almost all vaginal
369 *Ureaplasma*-positive cases, *Ureaplasma* was found on the surface of the placenta,
370 regardless of the delivery mode and vaginal *Ureaplasma* changes due to the antibiotic
371 regimen. Although there may be contaminations during delivery in PPRM cases, most
372 vaginal *Ureaplasma* may be ascending into amniotic fluid or placenta. Another
373 limitation is that the sample size was insufficient to validate the neonatal morbidity.
374

375 Conclusions

376 Almost all *Lactobacillus* spp. decreased while most vaginal *Ureaplasma* and *M.*
377 *hominis* increased after the antibiotic regimen. This suggests that *Ureaplasma* and *M.*
378 *hominis* became resistant to azithromycin. Future studies are needed to revalidate
379 current antibiotic therapy for PPROM because azithromycin-resistant *Ureaplasma* and
380 *M. hominis* are widespread in the vaginal tract.

381

382

383

384 Acknowledgements

385 We gratefully acknowledge the work of the medical staff of our center for their

386 assistance in specimen collection.

387

388 References


- 389 1. Mercer BM. Preterm premature rupture of the membranes. *Obstetrics and*
390 *gynecology*. 2003;101(1):178-93.
- 391 2. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of
392 preterm birth. *Lancet (London, England)*. 2008;371(9606):75-84.
- 393 3. Lorthe E, Torchin H, Delorme P, Ancel PY, Marchand-Martin L, Foix-L'Hélias
394 L, et al. Preterm premature rupture of membranes at 22-25 weeks' gestation: perinatal and
395 2-year outcomes within a national population-based study (EPIPAGE-2). *American*
396 *journal of obstetrics and gynecology*. 2018;219(3):298.e1-.e14.
- 397 4. Morris JM, Roberts CL, Bowen JR, Patterson JA, Bond DM, Algert CS, et al.
398 Immediate delivery compared with expectant management after preterm pre-labour
399 rupture of the membranes close to term (PPROMT trial): a randomised controlled trial.
400 *Lancet (London, England)*. 2016;387(10017):444-52.
- 401 5. Paramel Jayaprakash T, Wagner EC, van Schalkwyk J, Albert AY, Hill JE,
402 Money DM. High Diversity and Variability in the Vaginal Microbiome in Women
403 following Preterm Premature Rupture of Membranes (PPROM): A Prospective Cohort
404 Study. *PloS one*. 2016;11(11):e0166794.
- 405 6. Lowe J, Watkins WJ, Edwards MO, Spiller OB, Jacqz-Aigrain E, Kotecha SJ, et
406 al. Association between pulmonary ureaplasma colonization and bronchopulmonary
407 dysplasia in preterm infants: updated systematic review and meta-analysis. *The Pediatric*
408 *infectious disease journal*. 2014;33(7):697-702.
- 409 7. Lee J, Romero R, Kim SM, Chaemsaihong P, Yoon BH. A new antibiotic
410 regimen treats and prevents intra-amniotic inflammation/infection in patients with
411 preterm PROM. *The journal of maternal-fetal & neonatal medicine : the official journal*
412 *of the European Association of Perinatal Medicine, the Federation of Asia and Oceania*
413 *Perinatal Societies, the International Society of Perinatal Obstet*. 2016;29(17):2727-37.
- 414 8. Mercer BM, Miodovnik M, Thurnau GR, Goldenberg RL, Das AF, Ramsey RD,
415 et al. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture
416 of the membranes. A randomized controlled trial. *National Institute of Child Health and*
417 *Human Development Maternal-Fetal Medicine Units Network*. *Jama*. 1997;278(12):989-
418 95.
- 419 9. Mercer BM, Arheart KL. Antimicrobial therapy in expectant management of
420 preterm premature rupture of the membranes. *Lancet (London, England)*.
421 1995;346(8985):1271-9.
- 422 10. Kacerovsky M, Romero R, Stepan M, Stranik J, Maly J, Pliskova L, et al.
423 Antibiotic administration reduces the rate of intraamniotic inflammation in preterm

- 424 prelabor rupture of the membranes. American journal of obstetrics and gynecology.
425 2020;223(1):114.e1-.e20.
- 426 11. Siegler Y, Weiner Z, Solt I. ACOG Practice Bulletin No. 217: Prelabor Rupture
427 of Membranes. Obstetrics and gynecology. 2020;136(5):1061.
- 428 12. Seaman RD, Kopkin RH, Turrentine MA. Erythromycin vs azithromycin for
429 treatment of preterm prelabor rupture of membranes: a systematic review and meta-
430 analysis. American journal of obstetrics and gynecology. 2022;226(6):794-801.e1.
- 431 13. Hollander D. Diagnosis of chorioamnionitis. Clinical obstetrics and gynecology.
432 1986;29(4):816-25.
- 433 14. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. American journal of
434 respiratory and critical care medicine. 2001;163(7):1723-9.
- 435 15. Wynn JL, Wong HR, Shanley TP, Bizzarro MJ, Saiman L, Polin RA. Time for
436 a neonatal-specific consensus definition for sepsis. Pediatric critical care medicine : a
437 journal of the Society of Critical Care Medicine and the World Federation of Pediatric
438 Intensive and Critical Care Societies. 2014;15(6):523-8.
- 439 16. Byun R, Nadkarni MA, Chhour KL, Martin FE, Jacques NA, Hunter N.
440 Quantitative analysis of diverse Lactobacillus species present in advanced dental caries.
441 Journal of clinical microbiology. 2004;42(7):3128-36.
- 442 17. Kenyon SL, Taylor DJ, Tarnow-Mordi W. Broad-spectrum antibiotics for
443 preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial.
444 ORACLE Collaborative Group. Lancet (London, England). 2001;357(9261):979-88.
- 445 18. Prelabor Rupture of Membranes: ACOG Practice Bulletin, Number 217.
446 Obstetrics and gynecology. 2020;135(3):e80-e97.
- 447 19. Redelinguys MJ, Ehlers MM, Dreyer AW, Lombaard HA, Kock MM.
448 Antimicrobial susceptibility patterns of Ureaplasma species and Mycoplasma hominis in
449 pregnant women. BMC infectious diseases. 2014;14:171.
- 450 20. Navathe R, Schoen CN, Heidari P, Bachilova S, Ward A, Tepper J, et al.
451 Azithromycin vs erythromycin for the management of preterm premature rupture of
452 membranes. American journal of obstetrics and gynecology. 2019;221(2):144.e1-.e8.
- 453 21. Tanaka S, Tsumura K, Nakura Y, Tokuda T, Nakahashi H, Yamamoto T, et al.
454 New antibiotic regimen for preterm premature rupture of membrane reduces the incidence
455 of bronchopulmonary dysplasia. The journal of obstetrics and gynaecology research.
456 2019;45(5):967-73.
- 457 22. Gomez R, Romero R, Nien JK, Medina L, Carstens M, Kim YM, et al. Antibiotic
458 administration to patients with preterm premature rupture of membranes does not
459 eradicate intra-amniotic infection. The journal of maternal-fetal & neonatal medicine :

- 460 the official journal of the European Association of Perinatal Medicine, the Federation of
461 Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet.
462 2007;20(2):167-73.
- 463 23. Viscardi RM, Terrin ML, Magder LS, Davis NL, Dulkerian SJ, Waites KB, et
464 al. Randomised trial of azithromycin to eradicate *Ureaplasma* in preterm infants. *Archives*
465 *of disease in childhood Fetal and neonatal edition*. 2020;105(6):615-22.
- 466 24. Zhang W, Li L, Zhang X, Fang H, Chen H, Rong C. Infection Prevalence and
467 Antibiotic Resistance Levels in *Ureaplasma urealyticum* and *Mycoplasma hominis* in
468 Gynecological Outpatients of a Tertiary Hospital in China from 2015 to 2018. *The*
469 *Canadian journal of infectious diseases & medical microbiology = Journal canadien des*
470 *maladies infectieuses et de la microbiologie medicale*. 2021;2021:8842267.
- 471 25. Zhang S, Xu K, Liu SX, Ye XL, Huang P, Jiang HJ. Retrospective Analysis of
472 Azithromycin-Resistant *Ureaplasma urealyticum* and *Mycoplasma hominis* Cervical
473 Infection Among Pregnant Women. *Infection and drug resistance*. 2023;16:3541-9.
- 474 26. Kotecha S, Hodge R, Schaber JA, Miralles R, Silverman M, Grant WD.
475 Pulmonary *Ureaplasma urealyticum* is associated with the development of acute lung
476 inflammation and chronic lung disease in preterm infants. *Pediatric research*.
477 2004;55(1):61-8.
- 478 27. Kasper DC, Mechtler TP, Böhm J, Petricevic L, Gleiss A, Spergser J, et al. In
479 utero exposure to *Ureaplasma* spp. is associated with increased rate of bronchopulmonary
480 dysplasia and intraventricular hemorrhage in preterm infants. *Journal of perinatal*
481 *medicine*. 2011;39(3):331-6.
- 482 28. Okogbule-Wonodi AC, Gross GW, Sun CC, Agthe AG, Xiao L, Waites KB, et
483 al. Necrotizing enterocolitis is associated with *ureaplasma* colonization in preterm infants.
484 *Pediatric research*. 2011;69(5 Pt 1):442-7.
- 485 29. Jaffé A, Bush A. Anti-inflammatory effects of macrolides in lung disease.
486 *Pediatric pulmonology*. 2001;31(6):464-73.
- 487 30. Nair V, Loganathan P, Soraisham AS. Azithromycin and other macrolides for
488 prevention of bronchopulmonary dysplasia: a systematic review and meta-analysis.
489 *Neonatology*. 2014;106(4):337-47.
- 490 31. Razak A, Alshehri N. Azithromycin for preventing bronchopulmonary dysplasia
491 in preterm infants: A systematic review and meta-analysis. *Pediatric pulmonology*.
492 2021;56(5):957-66.
- 493 32. Chee WJY, Chew SY, Than LTL. Vaginal microbiota and the potential of
494 *Lactobacillus* derivatives in maintaining vaginal health. *Microbial cell factories*.
495 2020;19(1):203.


- 496 33. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis
497 is improved by a standardized method of gram stain interpretation. *Journal of clinical*
498 *microbiology*. 1991;29(2):297-301.
- 499 34. Kiss H, Kögler B, Petricevic L, Sauerzapf I, Klayraung S, Domig K, et al.
500 Vaginal *Lactobacillus* microbiota of healthy women in the late first trimester of
501 pregnancy. *BJOG : an international journal of obstetrics and gynaecology*.
502 2007;114(11):1402-7.
- 503 35. Petricevic L, Domig KJ, Nierscher FJ, Sandhofer MJ, Fidesser M, Krondorfer I,
504 et al. Characterisation of the vaginal *Lactobacillus* microbiota associated with preterm
505 delivery. *Scientific reports*. 2014;4:5136.
- 506 36. Payne MS, Newnham JP, Doherty DA, Furfaro LL, Pental NL, Loh DE, et al.
507 A specific bacterial DNA signature in the vagina of Australian women in midpregnancy
508 predicts high risk of spontaneous preterm birth (the Predict1000 study). *American journal*
509 *of obstetrics and gynecology*. 2021;224(2):206.e1-.e23.
- 510 37. Rampersaud R, Planet PJ, Randis TM, Kulkarni R, Aguilar JL, Lehrer RI, et al.
511 Inerolysin, a cholesterol-dependent cytolysin produced by *Lactobacillus iners*. *Journal of*
512 *bacteriology*. 2011;193(5):1034-41.
- 513

Figure 3 Change of microbial load of vaginal *Lactobacillus* spp. DNA before and after antibiotic regimen




*intravenous ampicillin 2 g every 6 hours for 2 days and a single oral dose of azithromycin 1 g followed by 5 days of oral amoxicillin 500 mg every 8 hours

Figure 1 Flowchart of the study population



*intravenous ampicillin 2 g every 6 hours for 2 days and a single oral dose of azithromycin 1 g followed by 5 days of oral amoxicillin 500 mg every 8 hours

Figure 2 Change of microbial load of vaginal *Ureaplasma* DNA before and after antibiotic regimen



medRxiv preprint doi: <https://doi.org/10.1101/2024.06.28.24099057>; this version posted July 1, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

*intravenous ampicillin 2 g every 6 hours for 2 days and a single oral dose of azithromycin 1 g followed by 5 days of oral amoxicillin 500 mg every 8 hours